instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
Since the vaccine is not available, a discussion of costs is not warranted. The piece does a nice job of presenting the results of the initial report in terms of absolute and relative risk reduction; however, absolute data is not provided for the secondary analyses. To its credit, the story clearly and effectively explained statistical significance as it relates to this research. As stated in previous coverage, the story reiterates that the benefits of the vaccine are modest and additional research is needed. Given that this is a follow-up report focused on newly released data, a discussion of the potential harms of the vaccine is not necessary. This story does an excellent job defining the different types of analyses used to evaluate the outcome data. The story also points out the results of the secondary analyses have been published in a peer-reviewed journal, suggesting the calculations have been checked for accuracy. This story does not engage in disease-mongering. This story does not provide commentary from any independent sources. In this case, a single comment from a biostatistical consultant would have provided helpful perspective. Given the nature of this follow-up story, a discussion on the existing alternatives to HIV prevention may not be warranted. This story makes it known that the vaccine is still in the testing phase and is not yet available. The story makes it clear that researchers have been working on an AIDS vaccine for decades. The story does not appear to be based on a press release.
answer:
AIDS Vaccine Is of Modest Help, Fuller Research Says


question:
"The story says that the average copayment for a month’s supply of some of the topical NSAID medications is around $30. It would have been nice to include the cost of comparable oral medications. Although the story explains the available evidence comparing topical NSAIDs to oral pain relievers, highlights the limited number of direct comparisons, and carefully states the general consensus of experts, all of this solid reporting is undermined by a focus on personal anecdotal evidence over quantifiable benefits. Indeed, the reporter claims one medication provided immediate relief, a statement at odds with clinical trials that conclude that it usually takes hours for patients to feel the pain-relief effects of topical NSAIDs. The story summarizes the reported side effects of topical NSAIDS. What’s more, the reporter points out that the potential risks in people who have other health problems or are taking other drugs have not been well studied. That insight is something we see too rarely. The story refers to a number of clinical trials and systematic reviews of the evidence. It highlights areas where evidence is lacking or inconclusive. It would have been helpful to point out that in placebo-controlled trials, almost as many people who received the placebo reported pain relief as did those who got the active medication. The story could have mentioned that the systematic review it referred to was published by the Cochrane Collaboration and also the sources of the other clinical trial reports, so that interested readers could more easily locate the original articles. The story does not exaggerate the common pains these drugs are intended to treat, but the personal anecdotes and opinions highlighted at the beginning and ending of the story are unrepresentative of the typical experiences reported by participants in clinical trials and create a powerful impression that is at odds with the evidence. The story includes quotes from several experts and points out that two of them have accepted consulting fees or research support from pharmaceutical companies. The essence of this story is an attempt to compare topical NSAIDs with pills and other pain treatments. As noted above, though, the story does not mention that most people with minor pains feel better after awhile even if they don’t take any pain relief medication. It also should have mentioned that the difference between placebo and active treatment groups in the clinical trials is often slim. The story reports that only three topical NSAIDs (nonsteroidal anti-inflammatory drugs) are approved for sale with a prescription in the United States, while several brands are sold over the counter in Europe. Part of the focus of the story is that NSAIDS have been around for a long time but only recently are being given a more serious scientific reassessment. As the story says, ""But a number of new controlled trials and meta-analyses like Dr. Moore’s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis."" The story includes several experts and mentions multiple studies."
answer:
Topical Gel Catches Up With Pills for Relief


question:
The outbreak initially took hold in eastern France, where hospitals have become overwhelmed, and has been spreading west. Doctors in the greater Paris region have said their intensive care units will be full by the end of the weekend. “We are fighting a battle that will take time,” Philippe said at a news conference. “The first two weeks of April will be harder than the two we have just lived through.”  To free up intensive care beds in worst-hit areas, the army and emergency workers were this weekend stepping up the transfer of patients to less-affected regions, using a military helicopter and a specially adapted train. By Saturday, the coronavirus had claimed 2,314 lives in France, with more than 37,575 confirmed cases, according to official figures. The government tally only accounts for those dying in hospital but authorities say they will be able to compile data on deaths in retirement homes from next week, which is likely to result in a marked increase in registered fatalities. In southern France, the Occitanie health authority reported 11 deaths in a nursing home near Montpellier. Dozens more elderly people are known to have died in separate cases. Health Minister Olivier Veran said he would be instructing care homes to isolate every single elderly resident in an effort to curb the virus among the most vulnerable. “We need to go further to protect the vulnerable in nursing homes,” Veran said. As the number of cases balloons and hospitals struggle, doctors, carers and police have complained of an acute shortage of protective gear. Veran said the government had ordered more than 1 billion face masks, most from China, to build up supplies, with the country using some 40 million every week during the crisis. Hospitals have scrambled to add intensive car beds and canceled non-essential operations. There were now 10,000 intensive care beds nationwide, double the capacity when the outbreak began, and another 4,500 were targeted, Veran said. But doctors warned beds alone were insufficient. “We lack manpower,” Djillali Annane, head of intensive care at the Raymond Poincare hospital on the edge of Paris, told BFM TV. Medical students are being drafted in to help ease the staffing crunch. A decision would be taken in a week on a further extension of an unprecedented lockdown beyond April 15, the prime minister said. People in France can only leave their homes to buy groceries, go to work if essential or seek medical care. “We will only be able to see the first signs of what impact the lockdown has had toward the end of next week,” Arnaud Fontanet of the Institut Pasteur told the same news conference.
answer:

Toughest weeks ahead in coronavirus fight, warns French PM.